Hongping Wei

Title: Innovations of Hongping Wei in Biological Agents

Introduction

Hongping Wei is a notable inventor based in Wuhan, China. He has made significant contributions to the field of biological agents, particularly through his innovative patents. With a total of 2 patents, his work focuses on developing lysins that target various bacterial species.

Latest Patents

Hongping Wei's latest patents include a lysin capable of killing Staphylococcus species. This invention discloses the amino acid sequence and the encoding gene sequence of the lysin, which remains active across a wide pH range. The lysin exhibits lytic activity in pH levels from 4 to 11 and can effectively kill multiple species in vitro, including methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) strains. Additionally, he has developed another lysin, ClyR, which can kill various species of Streptococci and Enterococci. ClyR shows good stability and is not sensitive to EDTA or high concentrations of NaCl. It maintains high activity in pH levels from 5 to 11 and has demonstrated no apparent toxicity in mice.

Career Highlights

Hongping Wei has worked with Wuhan Phagelux Bio-tech Company Limited and Phagelux, Inc. His innovative research has positioned him as a key figure in the development of biological agents for treating bacterial infections.

Collaborations

Some of his notable coworkers include Hang Yang and Junping Yu. Their collaborative efforts have contributed to the advancements in the field of biological agents.

Conclusion

Hongping Wei's contributions to the field of biological agents through his innovative patents highlight his role as a significant inventor. His work continues to pave the way for new treatments against bacterial infections.